Author

Kenneth Byrd

Observed name: Kenneth C. Byrd

Institutions: University of Kansas, University of Kansas Medical Center

Observed institutions: University of Kansas, University of Kansas Medical Center

OpenAlex ID: A5031429271

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

2023 · Matthew Joseph Wieduwilt, Jun Yin, et al. · Journal of Clinical Oncology · 51

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL

2026 · Hrishikesh K. Srinagesh, Vishal Gupta, et al. · Blood · 3

A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency

2020 · Ghulam Rehman Mohyuddin, Anthony Dominick, et al. · Journal of Cancer Education · 2

Bortezomib in the Treatment of Acquired von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance

2014 · Kenneth Byrd, Phu Truong · Kansas Journal of Medicine · 1

Positioned on Education

1966 · Jacqueline W. Childers, Mary E. Hazzard, et al. · AJN American Journal of Nursing

Works count: 5

Citation count: 57

H-index: 2

I10-index: 1